STRIANT (testosterone) by Auxilius Pharma is androgen receptor agonists [moa]. First approved in 2003.
Drug data last refreshed 11h ago · AI intelligence enriched 1mo ago
STRIANT is a buccal testosterone tablet approved in 2003 for treating testosterone deficiency in hypogonadal men. It works via androgen receptor agonism to restore physiological hormone levels. The extended-release formulation provides sustained systemic testosterone delivery through the buccal mucosa.
Product faces LOE pressure with moderate competitive intensity (30/100), indicating potential team restructuring and focus shift toward lifecycle extension or market consolidation.
Androgen Receptor Agonists
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial
Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis
Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
Testosterone Deficiency and Endothelial Dysfunction After Spinal Cord Injury
52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism
Worked on STRIANT at Auxilius Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moAuxilius Pharma is hiring 1 role related to this product
STRIANT roles are declining as the product approaches LOE, with zero current linked job openings. Career positions on this asset are increasingly specialized in defending market share and managing generic transition rather than growth initiatives.